| COVID-19 |
1 |
1 |
| Monoclonal Antibody |
0 |
0.82 |
| Biologic Therapy |
0 |
0.64 |
| Severe Acute Respiratory Syndrome |
0 |
0.37 |
| Immunization |
0 |
0.3 |
| Acute Respiratory Distress Syndrome |
0 |
0.29 |
| Intravenous |
0 |
0.15 |
| Otolaryngology |
0 |
0.1 |
| Adolescent Medicine |
0 |
0.07 |
| Allergy |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Dorsum |
0 |
0.07 |
| Epidemiology |
0 |
0.07 |
| Food and Drug Administration (FDA) |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Health Care Quality, Access, and Evaluation |
0 |
0.07 |
| Nose |
0 |
0.07 |
| Nursing Homes |
0 |
0.07 |
| Prisons |
0 |
0.07 |
| Third Space |
0 |
0.07 |
| Viral Load |
0 |
0.07 |
| Social Determinants of Health |
0 |
0.06 |